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Risk perceptionDespite the important benefits of maternal vaccination for pregnant women and newborns, vaccination
uptake is low in many European countries. Differences in vaccination policies and recommendations, as
well as concerns about vaccine safety can partly explain inadequate coverage rates and women’s hesi-
tancy to get vaccinated during pregnancy. This study aims to explore pregnant women’s experiences,
decision-making processes and perceptions towards maternal vaccination and maternal vaccine trials
in France, Germany, Italy, Spain and the United Kingdom. Qualitative interviews and focus groups were
conducted with 258 pregnant women identified through local research panels and snowballing. Topic
guides translated in local languages were designed to explore women’s awareness and perceptions of
maternal vaccination, and willingness to participate in vaccine trials during pregnancy. A thematic anal-
ysis was conducted. Pregnant women were found to have low awareness about maternal vaccination,
with many reporting not having received a recommendation to vaccinate from their doctors. Strong trust
in health professionals indicate that strengthened recommendations could improve vaccination uptake.
Vaccination decision-making in pregnancy was described in the context of a highly emotional period,
generating anxiety and fears around the safety of vaccines. Pregnancy was also discussed as a period dur-
ing which women develop nurturing and protective identities. However, depending on the information
they received as well as influences from experts, families and peers, women either perceived vaccination
as a threat to their babies’ safety or as a means to protect them. Attitudes towards maternal vaccine trials
were less ambiguous, with most pregnant women strongly rejecting the notion of taking part in trials.
While strategies to improve pregnant women’s awareness and perceptions of maternal vaccination are
needed, it is equally important to understand why healthcare professionals may not be recommending
vaccination. More coordinated strategies across Europe could help strengthen communication and trust
in maternal vaccination.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Maternal vaccination has the potential of reducing maternal
and newborn mortality and morbidity around the world by pro-
tecting pregnant women as well as providing passive immunity
to newborns [1–3]. The World Health Organization (WHO) recom-
mends vaccinating pregnant women against a number of diseases,
including seasonal influenza, as well as pertussis and tetanus in
certain high-risk areas [4–6]. However, recommendations and poli-
cies vary widely from one country to another, partly affected bydifferences in disease burden [7]. Most countries in Europe recom-
mend inactivated seasonal influenza vaccination to pregnant
women [8]. However, while pertussis or Tdap (tetanus, diphtheria,
pertussis) vaccination is recommended during pregnancy in some
countries such as the United Kingdom (UK), Spain, Germany or
Italy, it is only recommended before or after birth as part of a
cocooning strategy in other countries such as France [9–13]. Other
vaccines such as those against tetanus or Hepatitis B are generally
only recommended for pregnant women in high-risk groups,
including in these five European countries [9–12,14].
Despite the benefits of maternal vaccination for both mothers
and babies, uptake remains inadequate in many European coun-
tries. Data on vaccine coverage is also sparse: a 2018 report found
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influenza vaccine uptake among pregnant women [8]. Vaccine cov-
erage was found to range from 0.5% to 58.6% for the 2016–2017
season [8]. National data shows that influenza vaccination cover-
age among pregnant women was 43.7% in England [15] and
40.6% in Spain [16]. In both countries, vaccine coverage for pertus-
sis was higher, reaching 72.1% of pregnant women in England [17]
and 80.1% in Spain (Tdap) [18]. Maternal vaccination coverage was
lower in other countries, with studies reporting 10.9% of pregnant
women vaccinated against influenza in Germany [19], 6.5% in Italy
[20] and 7.4% in France [21] and 4.8% of pregnant women vacci-
nated against pertussis in Italy [20].
While the reasons behind low maternal vaccination uptake
rates in Europe are often country-specific, literature reviews have
found that the most important factors influencing uptake were
healthcare professional recommendations and vaccine safety per-
ceptions [22,23]. One study found that women who had received
a recommendation from a doctor were 10–12 times more likely
to receive a pertussis or influenza vaccine during pregnancy [22].
Low uptake among healthcare professionals themselves and lack
of recommendations from specific categories of healthcare profes-
sionals such as midwives is also a highly influential factor [24,25].
Furthermore, women who believed vaccines were unsafe for them-
selves or their unborn children were five times less likely to receive
a maternal vaccine [22]. Other factors that influence maternal vac-
cine uptake in Europe include but are not limited to low awareness
and lack of information [19,26–32], concerns that vaccines do not
work or are not useful [27,32–35], low perceived severity of
vaccine-preventable diseases [27,35], and the belief that the risks
of vaccination outweigh their benefits [19,28].
Despite the severe risks of certain infectious diseases for preg-
nant women and their babies, pregnant women have historically
been excluded from vaccine trials [36,37]. Recent disease out-
breaks such as H1N1 influenza or Zika have contributed to calls
from experts to include pregnant women in vaccine trials and to
design more vaccines with pregnant women in mind [36]. Preg-
nant women’s decision-making processes and perceptions of vac-
cine trials remain limited, with some studies reporting the
influence of factors such as perceptions around available evidence,
risks and trust [37,38].
This study aims to explore pregnant women’s experiences,
decision-making processes and perceptions towards maternal vac-
cination and maternal vaccine trials in Europe.2. Methods
The study described in this paper is part of a larger mixed-
method research project investigating global attitudes towards
maternal vaccination among pregnant women. This paper presents
findings from qualitative research conducted in five European
countries: France, Germany, Italy, Spain and the UK.2.1. Data collection
We collaborated with WIN/Gallup International Association
(WIN/GIA) to conduct semi-structured interviews and focus group
discussions with pregnant women over the age of 18 years. Partic-
ipants were recruited from research panels accessible from WIN/
GIA’s local partners. An additional snowballing method was used
to identify participants in Germany, Spain and the UK. In the UK,
some participants were also recruited through advertising posters
displayed in places such as antenatal clinics. In order to include dif-
ferent urban environments, participants were recruited from two
cities in France (Paris and Toulouse), Italy (Rome and Milan), Spain
(Madrid and Barcelona) and the UK (London and Birmingham).5674While focus groups in Germany were conducted in Munich and
Berlin, in-depth interviews participants were recruited from across
the country due to logistical challenges.
Pregnant women in their first, second or third trimester with
either positive or negative attitudes towards maternal vaccination
were purposively selected from each country. Between February
and May 2019, 20 semi-structured interviews and four focus
groups were conducted in each country by local experienced pro-
fessionals, briefed on the study objectives and under the supervi-
sion of the researchers. Two focus groups with women pregnant
for the first time and two with women pregnant for the second
time or more were conducted in each country, with 7 to 9 women
per focus group. Participants were compensated for travel and par-
ticipation in the research.
Topic guides were designed to obtain participants’ awareness,
experiences, perceptions, attitudes and decision-making factors
influencing vaccination and participation in vaccine trials in preg-
nancy, while encouraging them to share their views freely. Before
interviews or focus groups, participants were informed that their
participation in the study was voluntary and that they could refuse
to answer any questions. Verbal or written informed consent was
obtained from all participants. All study materials were developed
in English and translated by local translators.
2.2. Data analysis
With participants’ consent, interviews and focus groups were
audio-recorded. Anonymised transcripts were translated into Eng-
lish and imported into NVivo for analysis. One researcher coded
and analysed the transcripts by deductively drawing codes from
the topic guides, research objectives and analytical memos. An ini-
tial coding framework was developed by coding two transcripts
per country, using an inductive process to derive additional codes.
The final coding framework was then agreed for all countries of the
study (including countries not included in this paper) and the
remaining transcripts were coded by the researcher. Themes were
derived from the data by conducting a thematic analysis of differ-
ent aspects of maternal vaccination.
2.3. Data management and ethical approval
Data was collected by WIN/GIA according to strict industry
standards, such as those from the World Association for Public
Opinion Research (WAPOR). Ethical approval for secondary data
analysis was received by the London School of Hygiene & Tropical
Medicine (LSHTM) Ethics Committee in May 2019 (LSHTM ethics
ref: 17100).
All transcripts and analytical memos were anonymised to
ensure confidentiality, removing personal identifiers and using
numerical and country codes to refer to participants (i.e.
FR1. . .24 for France, DE1. . .24 for Germany, IT1. . .24 for Italy,
ES1. . .24 for Spain, and UK1. . .24 for the UK). In-depth interviews
were given the codes 1 to 20 and focus groups 21 to 24. All files
are stored on an LSHTM secure server and password-protected
computers. Data are stored according to LSHTM’s Records Reten-
tion and Disposal Schedule guidance.3. Results
The qualitative research included 258 pregnant women aged
between 18 and 46 years, 100 of which took part in interviews
and 158 in focus groups. The thematic analysis identified eight
key themes: 1) pregnant women’s awareness about maternal vac-
cination and healthcare professionals’ recommendations; 2)
changes in decision-making around vaccination associated with
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trust in healthcare professionals and health authorities; 5) influ-
ences on decision-making; 6) the importance of protection against
diseases; 7) fear and anxiety around vaccine safety; and 8) emo-
tions and perceptions around vaccine trials.3.1. Awareness about maternal vaccination and healthcare
professionals’ recommendations
Awareness about maternal vaccination was particularly low
among pregnant women in France, Germany and Italy. Women’s
knowledge about maternal vaccines depended on the official rec-
ommendations in their country, with women in France mostly dis-
cussing influenza vaccination and women in Germany, Italy, Spain
and the UK referring to both influenza and pertussis vaccination.
Some women blamed their low awareness on a lack of informa-
tion from healthcare professionals, with only a small number of
women reporting having received a recommendation in Italy: ‘‘I
have never read anything about it anywhere, and it was never offered
to me, not even during my previous pregnancies” (IT9). Furthermore,
even women who received a recommendation to vaccinate still felt
uninformed, blaming doctors for not spending enough time to
explain and discuss maternal vaccination: ‘‘The consultation lasts
5 min, I asked him the question if he thought it was ok to get vacci-
nated now, he said ‘yes, yes it would be very good, have a good day,
bye’” (FR10). Women in the UK and Germany also expressed feeling
pressured to vaccinate, with what was described by one woman as
a bullish approach: ‘‘Their approach can be a bit like bullish (. . .) how
they chase you down for vaccinations is like another level. . . Especially
if you say you’re not getting it then you’ll have hundreds of phone
calls” (UK23). A few women also reported receiving conflicting
advice or recommendations not to vaccinate from their doctor, par-
ticularly in France: ‘‘Once I had the confirmation of the gynaecologist,
she told me ‘don’t do it, it’s not worth it’, well then I decided not to do
it” (FR8).
Women who received recommendations for maternal vaccina-
tion felt more confident in vaccination, with many then deciding
to get vaccinated: ‘‘I have a relation of trust with my doctor. So, if
she said you have to do, I do it.” (FR22). Receiving positive advice
from multiple doctors reinforced this confidence. Satisfaction with
information received from doctors was particularly high in the UK,
with women valuing doctors who spend more time discussing and
listening to their concerns: ‘‘She said ‘I understand, you know, your
reservations because it’s not you anymore, it involves a little baby, like
you’re making a decision on behalf of someone else’ (. . .) the way she
handled it was very reassuring for me” (UK6).3.2. Decision-making around vaccination: The effect of pregnancy
Pregnancy was discussed as a period of change, with the devel-
opment of women’s nurturing and protective identities. Women in
the UK and Spain described a strong will to protect their babies and
described the importance of vaccination in this context. However,
the thought of receiving a vaccine during pregnancy also raised
discomfort and unease for pregnant women: ‘‘I get the impression
that I’m scared more now because I’m pregnant” (FR21). Anxiety
and doubt was associated with the injection of a foreign substance
into their bodies while carrying their unborn child: ‘‘When you
know you’ve got another human being that’s inside you, you’re just
double-thinking, you’re double-guessing: ‘‘Is it right? Is it wrong?”
(UK4). Some women explained these differences as a change in
perceptions about their own bodies, taking on a new responsibility
for their babies, while at the same trying to offer a safe pregnancy:
‘‘You’re not only responsible for yourself, you’re also responsible for
the life, which is growing in you” (UK7). These doubts led many5675women to refuse maternal vaccines, sometimes using highly emo-
tive language in their responses.
3.3. Information about maternal vaccination
Access to information was an important factor in decision-
making around maternal vaccination, with women reporting
receiving positive and negative information around vaccination,
including misinformation. Yet, women across all countries
described not having received any or sufficient information:
‘‘Unfortunately we are not informed enough about vaccines and I think
that’s why a lot of people don’t get vaccinated, or don’t dare to do it”
(FR8). Information about risks and benefits of vaccination, includ-
ing evidence of testing, was often requested, with women calling
for more unbiased and transparent information. Most women
agreed that information should come from their doctors, with
one woman stressing the importance of personal interactions:
‘‘Pregnancy is very personal and asking someone to put something
in their body, that’s not something you give them a leaflet about or just
information on a piece of paper or something. You need to speak
directly to someone” (UK8).
Despite the trustworthiness of online information being ques-
tioned, some women stated using the internet or social media to
look for information, particularly in France and the UK. Reassur-
ance was sought by consulting official and reliable websites, such
as those written by doctors or health authorities: ‘‘I know which
ones are reliable, because I search for them. I look for the updated ones,
that they are reliable, that the information looks checked and vali-
dated. I don’t go to websites where you don’t know who’s written
them” (ES9).
3.4. Trust in healthcare professionals and health authorities
Doctors were described as the most important influence in
decision-making around maternal vaccination: ‘‘I have no medical
notions so I trust them, and until now it has always been working
for me. Maybe that’s why I don’t have those fears that other mothers
can have, because I have all those doctors and I trust them” (FR14).
The strong trust expressed in doctors was either explained in rela-
tion to personal and long-lasting relationships with doctors or sci-
entific expertise: ‘‘That person has studied and has a certain amount
of medical knowledge, that’s why it’s hard for me not to trust a doctor”
(DE23).
Strong trust was also expressed towards health authorities, par-
ticularly in Italy. The knowledge that a vaccine has to go through a
process to be accepted and recommended in their country was
reassuring for women in Germany, Spain and the UK: ‘‘If you bring
a vaccination for pregnant women onto the German market, sufficient
studies must have been done in order to be allowed to put it on the
German market” (DE23).
However, a small number of women in France, the UK and Ger-
many expressed mistrust of health professionals and health
authorities. Some women believed doctors could be dishonest
and recommend vaccines because of their medical background or
financial incentives, including from health authorities or pharma-
ceutical companies, instead of scientific evidence: ‘‘When I found
out that GPs get paid per vaccination that they give to each child, that
then started making me think (. . .) this is just a business” (UK23). Mis-
trust of pharmaceutical companies due to financial motives was
raised in all countries.
3.5. Influences on decision-making
In addition to doctors, influences in decision-making were
reported from other pregnant or previously pregnant women,
whether mothers, sisters or friends: ‘‘I always ask people who have
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[which vaccinations] (. . .), so I tend to go on that because I can see
the baby, it’s healthy” (UK22). While family was also seen a source
of influence in women’s decisions, the partner’s role in decision-
making was more ambiguous, with some women describing them
having an active role in the decision (e.g. ‘‘You still need to talk
about it with our partner and I believe that the partner has his word
to say” (FR15)) and others explaining that their partners are not
involved in such decisions (e.g. ‘‘My husband does that think like
‘do whatever you think’ and sometimes that’s not really very helpful”
(UK24)). External influences were either positive or negative, with
women in France reporting having received recommendations
from friends not to get vaccinated. Finally, vaccination decision-
making was also discussed as a personal decision that pregnant
women should make autonomously, particularly in France: ‘‘When
I ask a question, I already have the answer, I already know what I must
do” (FR2)
3.6. The importance of protection against diseases
The importance of protection against diseases offered by vacci-
nation was more often discussed in relation to women’s babies
rather than themselves: ‘‘I wasn’t afraid for me but more for the foe-
tus” (FR3). This was an important motivator for women to get vac-
cinated, particularly in Spain and the UK: ‘‘I feel that my primary
purpose is to protect the unborn child, so if that’s [vaccinating] what
I need to do then I’ll do that.” (UK2). Vaccination decision-making
was dependent on the types of diseases prevented by vaccines,
with a priority given to vaccines against diseases perceived as
life-threatening. More concerns were raised about the dangers of
pertussis and tetanus than influenza. Emotions associated with
the risk of these diseases also played a role in decision-making:
‘‘We live in a culture of fear and that’s how we work. If (. . .) it [disease]
doesn’t feel very alarming, then I will surely pass [on vaccination]”
(ES20). Women who did not perceive the benefits of vaccines or
the severity of vaccine-preventable diseases were less confident
in getting vaccinated: ‘‘As long as it was only about the flu and not
about a deadly disease, I didn’t see why I should take the risk”
(DE10). Community protection was discussed by some women in
France and the UK, who stated they would consider getting vacci-
nated to protect those around them: ‘‘It’s not for you essentially. If a
lot of people get [the vaccine] in this area then no-one has the disease”
(UK23).
The risk of contracting diseases was also discussed as a factor
influencing decision-making, with women in France mostly dis-
cussing the risk of influenza and women in Italy, Spain and the
UK expressing concerns about recent epidemics of pertussis.
Women who did not feel at risk of contracting vaccine-
preventable diseases, for example because they remained at home,
were less willing to accept maternal vaccines. Questions around
the effectiveness of vaccines, particularly influenza, were also
raised: ‘‘I heard a lot of things around me and on the internet about
people who have been vaccinated and who still had the flu. So I mean,
why do it if it’s to have the flu after?” (FR8). Two women in Italy
questioned whether immunity is passed on to babies when preg-
nant women are vaccinated.
3.7. Fear and anxiety around vaccine safety
Concerns about the safety of maternal vaccination were com-
mon across all countries and constituted an important deterrent
for accepting vaccination. Women discussed concerns about vac-
cine ingredients and adjuvants as well as a variety of side effects,
including miscarriage, autism, or development disorders. The
belief that influenza vaccination could cause the flu was also com-
mon across all countries. Strong emotional reactions, including fear5676and anxiety were observed in relation to the perceived risks of vac-
cination for unborn babies: ‘‘You think: will it affect the baby? You
suffer. Suffering. I got it [vaccine] and I was scared” (ES21). Antici-
pated guilt and responsibility for babies were commonly dis-
cussed: ‘‘You don’t know how to proceed afterwards. What do you
do if it goes wrong for the baby?” (FR2). Anxiety was often associated
with women unable to see their foetus and detect problems: ‘‘If
something goes wrong in my womb, it’s going to be my fault and I
won’t see it.” (FR21).
Vaccination was described as risk-taking by women in France,
Germany, Italy and the UK, with some women comparing vaccina-
tion to smoking or drinking alcohol during pregnancy: ‘‘Some
women don’t stop smoking and I imagine that these women would
be also less concerned about vaccinations” (DE23). Taking risks dur-
ing pregnancy was perceived as unacceptable by some women,
with some referring to the fact that women are not supposed to
take any medicine during pregnancy: ‘‘They tell us that small
medicines are forbidden, even cough syrup is forbidden, so I don’t
really understand why [vaccination] would be authorised” (FR2).
For some pregnant women in France, Italy and the UK, staying
healthy was associated with avoiding vaccination and using natu-
ral alternatives: ‘‘I want my body to stay healthy. I prefer to treat
myself with natural products” (FR4). Alternatives included home-
opathy as well as limiting exposure to diseases by washing their
hands or staying at home: ‘‘Then I’ll make sure not to catch it. There
is something where? All around Spain? Where? All Spain? Maybe then
I don’t leave my home” (ES11).
3.8. Emotions and perceptions around vaccine trials
Awareness about vaccine trials in pregnancy was low in all
countries. Most women were unwilling to take part in a vaccine
trial, expressing strong emotional and shocked responses, particu-
larly in France and Italy: ‘‘Are you saying that some pregnant women
volunteer to be guinea pigs?!?!? Oh my god!!! I would never do it”
(IT10). Some women in Italy were judgmental of pregnant women
willing to take part in trials, referring to them as ‘irresponsible’ and
‘crazy’. Fear was a common reaction among women, who described
taking part in trials as a sacrifice.
Concerns about side effects and possible risks for babies were
the most common reasons provided for refusing to take part in vac-
cine trials: ‘‘It’s a study where you try to find out the effects of a cer-
tain product on pregnant women and their babies. You don’t know the
risks yet, you will see the effects during the trial and I am not willing to
put the health of my baby in danger” (DE9). The fear of facing uncer-
tainty with an ‘experimental’ product was also important, with
many women using the word ‘guinea pig’ to characterise how they
would feel if they took part in a trial. Some expressed disgust in
relation to the role of the pharmaceutical industry: ‘‘I think there
is a lot of vested interests behind all this, the pharmaceutical business,
an economic benefit, and I don’t want to take part in any of that. In
fact, it’s disgusting” (ES20).
In all countries except France, some women remained opened
to the idea of participating in trials during pregnancy, conditional
on certain factors such as receiving more information or recom-
mendations from their doctors. Most of these women explained
they would only accept to take part if they were told the vaccine
was safe: ‘‘I probably wouldn’t consider it like I say, unless there’s
some compelling research or a previous study that has shown it was
safe” (UK17). However, a couple of women in Germany trusted that
trials would never be conducted with pregnant women if they
were unsafe: ‘‘I think I would be chilled about it because I would
assume that they wouldn’t give anything to pregnant women that
could actually be harmful” (DE7). Women were also more likely to
take part in trials for life-threatening or dangerous diseases: ‘‘It
would have to be a huge pay-off in the sense of (. . .) establishing a
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the embryo” (UK2). Financial compensation was only discussed as a
convincing argument by a couple of women in France and Spain.
A few women in Germany, Spain and the UK also responded
they would consider taking part in trials to help other pregnant
women and to improve healthcare and science: ‘‘We need trials
and research to continue and go forward so that it makes it safer for
everyone. (. . .) I’ve always been interested in scientific studies, so I
think those kinds of things may well be very interesting” (UK6). Some
women in these countries also referred to pregnant women who
take part in trials as ‘brave’, respecting and thanking them for their
‘impressive’ choices.4. Discussion
Maternal vaccination is an essential component of strategies
aimed at protecting mothers and newborns from potentially sev-
ere infections [1]. Given that maternal vaccination uptake
remains low in most European countries, understanding factors
influencing pregnant women’s willingness to receive a vaccine
is important [8]. This qualitative study provided an overview of
pregnant women’s experiences, decision-making processes and
perceptions towards maternal vaccination and maternal vaccine
trials in France, Germany, Italy, Spain and the UK. Some differ-
ences in the themes identified through the qualitative analysis
were noted between countries, with women in Spain and the
UK for example more often discussing the protective benefits of
vaccination and women in France and Italy expressing stronger
emotional reactions against vaccine trials. Furthermore, while
women across all countries expressed strong trust in HCPs, they
experienced different recommendations and advice from HCPs
in relation to maternal vaccination, with women in Italy reporting
less recommendations and therefore awareness about maternal
vaccination, women in France reporting recommendations not
to vaccinate and women in Germany and the UK particularly sat-
isfied with the information they had received. Future quantitative
studies should confirm such differences and possible associations,
as they constitute important insights for the development of tar-
geted and context-specific interventions to improve maternal vac-
cination uptake.
Despite national recommendations, pregnant women’s aware-
ness about maternal vaccination was low, with women reporting
a lack of information and recommendations from doctors. While
this confirms findings from previous studies, it also highlights
the need for stronger communication and information campaigns
to raise awareness about the benefits of maternal vaccination
[22,26–28]. Further research should also be conducted in countries
where maternal vaccination is not part of routine antenatal ser-
vices, as this could further impact women’s awareness about vac-
cination. As women also reported strong influences from their
peer networks, communication campaigns could also focus on
engaging communities and peers, for example by involving them
in discussions around vaccination or by using them as peer educa-
tors [39].
However, increasing access to information may not be sufficient
to rebuild confidence in and uptake of maternal vaccination. A
study in Spain found that pregnant women with higher health lit-
eracy were more likely to decline immunisation, with the authors
suggesting this could be due to women seeking information online
[29]. Our study found that despite women reporting that the inter-
net and social media are not trustworthy, they would still use it to
research information around vaccination. Pregnant women who
used social media to look for information about maternal vaccina-
tion were found to be less likely to receive pertussis vaccination
during pregnancy in a study in the UK [40]. While ensuring preg-5677nant women have access to clear and factual information about
maternal vaccination is important, strategies should also include
structural changes such as the removal of misinformation from
social media platforms to prevent exposure of pregnant women
to misinformation, as well as interventions to empower and train
women to assess and evaluate health information [41].
Pregnant women expressed strong trust in their doctors,
explaining maternal vaccine recommendations from midwives,
general practitioners, or gynaecologists were a decisive factor for
vaccine acceptance. This confirms findings from previous studies
that have found associations between women’s vaccine uptake
and receiving a recommendations from healthcare providers
[26,28,30,31]. However, this trust can constitute a barrier to mater-
nal vaccination if doctors do not recommend vaccination or if they
recommend against it, as was seen in this study. A European report
states that while 96% of general practitioners in the UK and 93% in
Spain would recommend influenza vaccination to pregnant
women, only 83% of general practitioners would do so in France
[42]. Understanding the reasons behind doctors’ recommendation
practices is therefore essential. Studies from various European
countries identified similar issues than the ones raised by pregnant
women, such as a perceived lack of official recommendations for
maternal vaccination as well as concerns about vaccine safety
and effectiveness [24,31,43,44]. Furthermore, healthcare profes-
sionals’ recommendations for maternal vaccination were found
to be associated with their own vaccination status, pointing to pos-
sible vaccine hesitancy issues [25,43]. Vaccine perceptions are also
known to vary among different types of healthcare professionals,
with midwives and nurses, who are generally more trusted by
pregnant women, showing less confidence in vaccination and will-
ingness to recommend vaccines to pregnant women than other
doctors [25].
Pregnant women’s trust in their doctors was found to be based
on the perceived scientific expertise of doctors as well as reassur-
ing, personal and long-term relationships with them. This shows
that vaccine recommendations by themselves might not be suffi-
cient, and the manner in which doctors recommend vaccination
could be equally as important [39]. Many women were disap-
pointed at the lack of explanations they received and the feeling
their doctors did not have time to talk about vaccination. The per-
ceptions that doctors were forcing vaccines, sometimes even being
judgmental or dishonest, have the potential of eroding women’s
trust in their doctors and in vaccination overall.
One study in the UK found that 25% of healthcare professionals
were not confident in discussing vaccination with pregnant
women [45]. These findings highlight the need for stronger com-
munication training for healthcare professionals to improve their
confidence in addressing pregnant women’s concerns as well as
explaining the need for maternal vaccination [46,47]. Insufficient
evidence exists on effective communication strategies to improve
vaccine uptake and confidence in pregnancy, but studies seem to
show the importance of personal interactions and emotional
responses from healthcare professionals, such as empathy [39,48].
Vaccination decision-making during pregnancy was described
in the context of a highly emotional time, with women reporting
a range of strong emotions, from fear to anxiety and guilt. These
were in part explained by a growing sense of responsibility and
desire to protect their children. For some women, pregnancy was
the first time they were required to make a decision about vaccina-
tion, which could create uncertainty and anxiety. Furthermore, it
was shown that pregnant women’s experiences with vaccination
in pregnancy can impact their future attitudes towards childhood
vaccination [49,50]. Future research should be conducted to
explore the possible association between women’s perceptions
and whether this is a first time pregnancy or whether they have
other children.
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women’s decisions to accept or refuse vaccination. While some
women expressed fears about the risk of diseases and the desire
to protect their babies – and even communities – against possible
threats through vaccination, others identified vaccination as the
threat. Exploring how women perceive different maternal vaccines
(e.g. influenza vs pertussis or COVID-19) is therefore crucial.
Women reported anxiety, fear and anticipated guilt as reasons
for refusing vaccines, mostly in relation to vaccines’ safety and con-
cerns about side effects for their babies. While pregnant women’s
concerns about vaccine safety is known to contribute to vaccine
hesitancy and refusal [22,23], this study found that women placed
vaccination in the context of the long tradition of avoiding any type
of risk during pregnancy. As women have repeatedly been told to
avoid risks such as smoking, drinking alcohol or even taking certain
medications, the notion of receiving a vaccine while they are preg-
nant is unconceivable for some. Communication strategies focus-
ing on vaccination in the context of other antenatal care
interventions and possible risks will therefore be required to
change women’s perceptions and establish maternal vaccination
as a safe intervention. Insufficient evidence exists on the effective-
ness of such strategies with pregnant women, which warrants fur-
ther research.
Contexts of high uncertainty have been shown to heighten anx-
ieties and emotional reactions to vaccination [51,52]. While this
was visible in this study, with pregnant women expressing con-
cerns about being unable to see their unborn babies’ reactions to
vaccines, it was even more important in women’s discussions
around vaccine trials. Emotions such as anxiety, fears and even dis-
gust were heightened in relation to safety concerns around vaccine
trials. Taking part in vaccine trials was seen as an unnecessary risk
in the context of pregnancy, with no or little perceived individual
benefits. Only a few women discussed taking part in trials as a
means to contribute to the progress of science or to benefit preg-
nant women in the future. It would be important to understand
how such perceptions may evolve in the context of vaccine trials
during global pandemics, such as COVID-19. While many have
stressed the need to increase the participation of pregnant women
in clinical trials to obtain more data on the safety and effectiveness
of important public health interventions such as vaccination, it
raises important ethical issues [53,54]. In addition to addressing
the concerns pregnant women may have about participating in
such trials, it is therefore important to develop stronger guidance
on issues such as informed consent, and risk benefits analyses
[55,56].
Our study has several limitations. Our sample was relatively
homogenous, with participants mostly coming from urban areas.
It is possible different themes would be identified in a more diverse
or rural sample. While no associations between socio-economic
variables such as education, age, or ethnicity and vaccine confi-
dence can be made based on qualitative data, it is possible that
these factors influenced some of the results. Furthermore, while
one of the strengths of this study was the analysis of international
data from five European countries, more local research in each of
the countries would allow more contextual insights. Although
the impact of interviewers on participants’ responses in qualitative
studies is non-negligible, it was limited by using trained local
researchers and good fieldwork and analysis practices as well as
comprehensive analysis of the entire data set.
This study explored pregnant women’s perceptions and
decision-making practices around maternal vaccination in Europe,
highlighting the important role of trust and emotions as well as
healthcare professionals’ recommendations in women’s decisions.
Some differences across countries were also identified, showing
the need for targeted responses. However, the range of different
policies for maternal vaccination across Europe may be contribut-5678ing to the inadequate recommendation practices by healthcare
professionals and women’s hesitancy to get vaccinated. While this
warrants further research, more coordinated strategies across the
region could strengthen communication and overall trust in mater-
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